Nkarta (NKTX) Income from Continuing Operations (2019 - 2026)
Nkarta's (NKTX) quarterly Income from Continuing Operations came in at 34037000.0 in Q1 2026, up 9.81% year-on-year from 30997087.43 in Q1 2025, and down 0.85% quarter-over-quarter from 33751000.0 in Q4 2025.
Nkarta (NKTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Nkarta's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 34037000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 9.81% year-over-year to 34037000.0 in Q1 2026; TTM through Mar 2026 was 190453000.0, a 42.28% decrease from a year earlier, with the FY2025 full-year figure at 257866000.0, down 99.55% from the prior year.
- Income from Continuing Operations eased to 34037000.0 in Q1 2026 per NKTX's latest filing, from 33751000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 26586000.0 in Q1 2022 and bottomed at 180223000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 37738000.0 (2025), against an average of 65375411.76.
- Across the five-year window, Income from Continuing Operations plunged 514.86% in 2022 and surged 82.94% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 36080000.0 in 2022, then decreased by 20.49% to 43473000.0 in 2023, then climbed by 29.15% to 30801000.0 in 2024, then declined by 9.58% to 33751000.0 in 2025, then decreased by 0.85% to 34037000.0 in 2026.
- Per Business Quant, the three latest NKTX Income from Continuing Operations figures stand at 34037000.0 (Q1 2026), 33751000.0 (Q4 2025), and 60515000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | -34.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.04 Mn |
| Dec 31, 2025 | -33.75 Mn |
| Sep 30, 2025 | -60.52 Mn |
| Jun 30, 2025 | -62.15 Mn |
| Mar 31, 2025 | -37.74 Mn |
| Dec 31, 2024 | -30.80 Mn |
| Sep 30, 2024 | -34.57 Mn |
| Jun 30, 2024 | -30.75 Mn |
| Mar 31, 2024 | -60.42 Mn |
| Dec 31, 2023 | -43.47 Mn |
| Sep 30, 2023 | -169.42 Mn |
| Jun 30, 2023 | -180.22 Mn |
| Mar 31, 2023 | -36.65 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -88.41 Mn |
| Jun 30, 2022 | -145.81 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -39.69 Mn |
| Jun 30, 2021 | -23.71 Mn |